Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Gross Margin: 2020-2025

Historic Gross Margin for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to 53.46%.

  • Insight Molecular Diagnostics' Gross Margin rose 998.00% to 53.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 54.73%, marking a year-over-year increase of 5078.00%. This contributed to the annual value of 39.34% for FY2024, which is 1186.00% up from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Gross Margin is 53.46%, which was down 20.88% from 67.57% recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Gross Margin peaked at 72.47% during Q4 2021, and registered a low of -401.49% during Q3 2022.
  • Over the past 3 years, Insight Molecular Diagnostics' median Gross Margin value was 48.08% (recorded in 2024), while the average stood at 38.44%.
  • In the last 5 years, Insight Molecular Diagnostics' Gross Margin spiked by 921,953bps in 2021 and then plummeted by 31,348bps in 2022.
  • Over the past 5 years, Insight Molecular Diagnostics' Gross Margin (Quarterly) stood at 72.47% in 2021, then tumbled by 8,233bps to -9.85% in 2022, then slumped by 2,741bps to -37.26% in 2023, then soared by 7,730bps to 40.04% in 2024, then soared by 998bps to 53.46% in 2025.
  • Its Gross Margin stands at 53.46% for Q3 2025, versus 67.57% for Q2 2025 and 61.97% for Q1 2025.